Dr. Sheetal Kircher with Lurie Cancer Center says some signs of a pulmonary embolism include fatigue and shortness of breath.

FLAME analysis suggests COPD exacerbation risk spikes for 3 months after stopping LAMA or ICS, underscoring adherence and careful step-down.

GSK's Nucala (mepolizumab) has received European Commission approval as an add on maintenance treatment for uncontrolled COPD. The approval is supported by positive Phase III MATINEE trial results.

A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the ...

GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." ...

The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

Australia: A new study has found that among people with chronic obstructive pulmonary disease (COPD), beta-blocker therapy ...

Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health and Care Excellence (NICE), recommending it for NHS reimbursement as an ...

Drugmaker GSK said on Friday that the European Commission has approved Nucala (mepolizumab) as an add‑on maintenance ...

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...